8 results about "Mitochondrial protein" patented technology

The invention discloses engineering mitochondria enriched with alpha2delta2 protein, the expression level of the alpha2delta2 protein in the mitochondria is higher than that of natural mitochondria, the expression quantity of the alpha2delta2 protein is 15-40 times that of the natural mitochondria, and the alpha2delta2 protein is enriched in the outer membrane of the mitochondria. The invention also discloses a preparation method of the engineered mitochondria enriched with the alpha2delta2 protein. The invention also discloses an application of the engineered mitochondria enriched with the alpha2delta2 protein in preparation of medicines for preventing and / or treating fibrosis diseases. In-vitro experiments prove that the engineered mitochondria can significantly enhance the ability of inhibiting fibroblast activation and collagen secretion, and the effect of the engineered mitochondria is far better than that of common mitochondria. The invention provides a brand-new and effective organelle level treatment scheme for solving the clinical problem of fibrosis.

The invention discloses a phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting. The phototherapy nano-drug is ATO / CR nano-particles formed by self-assembling a compound CR and atorvaquone under the action of distearoyl phosphatidyl ethanolamine-polyethylene glycol; the structure of the compound CR is shown as a formula I in the specification. The invention discloses an application of the phototherapy nano-drug with mitochondrial / STAT3 protein double-site targeting in preparation of drugs for treating tumors. The phototherapy nano-drug can target mitochondria and STAT3 protein in tumor cells through ATO, and can also passively target tumor sites through the high-permeability long-retention effect of nano-particles, so that more nano-therapeutic agents are enriched around tumors, and the curative effect is improved. The phototherapy nano-drug provided by the invention has good photothermal performance, can effectively enhance the PTT effect of gastric cancer, and exerts the tumor synergistic treatment ability by promoting cell apoptosis, inhibiting angiogenesis and hindering the cell cycle.

The application discloses an application of an ND-42 related plasmid in preparation of a Drosophila mitochondrial protein expression kit, and the kit is mainly designed for a preparation method of mitochondrial related protein expression in S2 cells for the ND-42 protein. The kit constructs a pUAS-attB-3xHA-ND-42CDS full-length plasmid, a pUAS-attB-3xHA-ND-42-DNK-dom plasmid and a pUAS-attB-3xFlag-Nap1CDS full-length plasmid. The kit mainly uses a UAS-Gal4 system to realize the expression of the ND-42 protein, the DNK domain of the ND-42 protein and the Nap1 protein. The results of immunoprecipitation and Western blotting show that the Nap1 protein can strongly interact with the ND-42 protein. Further experimental observation shows that the Nap1 protein can also strongly physically combine with the DNK domain of the ND-42 protein. The kit can provide an important research method for the function and mechanism exploration of the mitochondrial related protein.

There is provided a method of promoting survival and / or function of an amyotrophic lateral sclerosis (ALS) or ALS-like motor, the method comprising contacting the motor neuron with an agent capable of reducing mitochondrial protein acetylation, particularly an agent selected from a deacetylase activator, such as nicotinamide (NAM) and 7-hydroxy-3-(4′-methoxyphenyl) coumarin (C12), or an acetyltransferase inhibitor, such as GCN5L1 siRNA of SEQ ID NO: 1. Also provided are related agents, oligonucleotides, uses and methods of identifying agents.

Provided herein are methods, kits, and assays for identifying and quantifying a mitochondrial protein in a sample using mass spectrometry. Also provided herein are methods, kits, and assays for determining a mitochondrial protein biomarker signature for a subject using mass spectrometry.

The invention provides application of an ACLY gene medicine in preparation of a medicine for treating and preventing cardiomyopathy. The sequence of the ACLY gene is SEQ ID NO.1, and the cardiomyopathy comprises cardiac dysfunction caused by isoprenaline and thoracic aorta constriction. A cardiomyopathy drug AAV9-cTnT-ACLY taking ACLY in mitochondria as a drug target is developed by researching the relationship between ACLY and the occurrence mechanism of cardiomyopathy, the drug is based on an AAV9 adeno-associated virus vector, an ACLY gene segment is inserted into the vector, and finally animal experiments are performed to verify the effect of the drug. It is found that the high-expression mitochondrial targeting ACLY can significantly improve the expression and activity of ACLY in myocardial cells, inhibit mitochondrial protein acetylation and significantly improve the heart function of mice, and has very high clinical value.

The application provides application of a small molecule compound S89 in preparation of a drug for treating diseases related to mitochondrial abnormalities, and belongs to the field of medicines. The small molecule compound S89 can enhance the enzyme activity of mitochondrial MFN1 protein, has the effects of promoting mitochondrial fusion of cells, restoring mitochondrial morphology and function, and can improve axon degeneration of motor neurons of CMT2A patients, and can be used for preparing a drug for treating CMT2A type Charcot-Marie-Tooth disease and a heart ischemia-reperfusion injury syndrome, and can also be used for preparing a drug for inhibiting proliferation of lung cancer cells.

The present invention discloses superoxide-specific quinone methide precursors (QMP-SOs) that enable proximity labeling and chemoproteomics to investigate superoxide redox biology. QMP-SOs are activated by superoxide to generate a reactive quinone methide intermediate that covalently tags nearby proteins. These probes exhibit high selectivity toward superoxide over other ROS, enabling protein labeling in superoxide-rich cellular compartments. QMP-SOs are compatible with fluorescence imaging and tandem mass tag (TMT)-based mass spectrometry, facilitating visualization of superoxide dynamics and identification of superoxide-regulated proteins. In menadione-treated HepG2 cells, QMP-SO-TMT profiling identified mitochondrial proteins including DJ-1 and DLDH as redox-sensitive targets, linking superoxide stress to cell survival and metabolism. The QMP-SO platform uniquely combines spatial proximity labeling with superoxide specificity, allowing previously inaccessible insights into dynamic and localized redox signaling. This invention is broadly applicable in studying superoxide-mediated processes and holds potential for therapeutic target discovery in diseases driven by oxidative stress, including cancer, aging, and neurodegeneration.